Bausch Health Companies Inc. (BHC)
| Market Cap | 2.46B |
| Revenue (ttm) | 10.03B |
| Net Income (ttm) | 362.00M |
| Shares Out | 370.52M |
| EPS (ttm) | 0.97 |
| PE Ratio | 6.88 |
| Forward PE | 1.63 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,971,514 |
| Open | 6.65 |
| Previous Close | 6.69 |
| Day's Range | 6.56 - 6.77 |
| 52-Week Range | 4.25 - 9.50 |
| Beta | 0.40 |
| Analysts | Hold |
| Price Target | 9.00 (+35.34%) |
| Earnings Date | Oct 29, 2025 |
About BHC
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern... [Read more]
Financial Performance
In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for BHC stock is "Hold." The 12-month stock price target is $9.0, which is an increase of 35.34% from the latest price.
News
Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal Disease
Expansion improves access to treatment options within periodontal care and helps strengthen partnerships with dental professionals within these populations. LAVAL, QC / ACCESS Newswire / November 5, 2...
Bausch + Lomb to Hold Investor Day on Nov. 13
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will hold an investor day on T...
Why Bausch Health Is A Buy After Rising 10% On Third-Quarter Results
Bausch Health Companies delivered strong Q3 results, with revenue up 6.8% year-over-year and EPS beating estimates by $0.10. BHC's growth is driven by successful product launches like Cabtreo, robust ...
Bausch Health Companies Inc. (BHC) Q3 2025 Earnings Call Transcript
Bausch Health Companies Inc. ( BHC) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Garen Sarafian - VP & Head of Investor Relations Thomas Appio - CEO & Director Jean-Jacques...
Bausch Health Announces Third Quarter 2025 Results
Third Quarter Consolidated Revenues of $2.68 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $179 ...
Activist Investor Seeks Strategic Overhaul At Contact Lens Maker Cooper, Suggests Merger With Bausch + Lomb
Activist investor Jana Partners has reportedly taken a stake in The Cooper Companies (NASDAQ:COO) and is pressing the medical-device maker to evaluate strategic alternatives — including a potential me...
Bausch Health Announces Results of Special Meeting of Shareholders
LAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. (the "Company") (NYSE:BHC)(TSX:BHC) today announced the results of the special meeting of shareholders held on October 7, 2...
Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV
The Balancing Act airing on Lifetime will showcase how innovative treatments Thermage® FLX, Clear + Brilliant®, and Fraxel FTX™ offer energy-based treatment options that help maintain a youthful appea...
Bausch Health to Announce Third Quarter 2025 Results on October 29
LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2025 financial results after market close on Wednesday, October 29, 2025....
Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry
Designed for dental professionals, OraTalks connects leading voices with insights to spark meaningful dialogue. Nine-episode inaugural season hosted by industry thought leader Melissa K.
Bausch Health: Repricing Continues As Deleveraging Gains Traction
Bausch Health remains a Buy as the market overstates debt and patent risks, while the business shows stable cash generation and operational momentum. Q2 results confirmed growth in core segments, impr...
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAV...
Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the Ameri...
Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Clinical Ophth...
Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System
LAVAL, QC / ACCESS Newswire / September 5, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aest...
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025
LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ:DRRX) t...
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan
LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced that...
Bausch + Lomb board members resign after Icahn agreement ends
Bausch + Lomb said on Monday Brett Icahn and Gary Hu have resigned from its board of directors after the termination of the agreement with billionaire Carl Icahn and some of his affiliates.
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
LAVAL, QC / ACCESS Newswire / August 15, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced that Paulson Capital Inc. and certain affiliates and...
Why Bausch Health Stock Surged By Nearly 20%
Bausch Health surged by nearly 20% on high volume on Monday, rebounding from a post-earnings sell-off driven by high risk and debt concerns. Q2 results beat revenue and GAAP EPS estimates, with strong...
Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners
For the Sixth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC / ACCESS Newswire / August 7, 2025 / Bausch Health Companies Inc. (NYSE:BH...
Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript
Bausch Health Companies Inc. (NYSE:BHC) Q2 2025 Earnings Conference Call July 30, 2025 5:00 PM ET Company Participants Garen Sarafian - VP & Head of Investor Relations Jean-Jacques Charhon - Executiv...
Bausch Health Announces Second Quarter 2025 Results
Second Quarter Consolidated Revenues of $2.53 billion, up 5% on a Reported basis and 4% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health Compani...
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
Bausch Health Companies Inc. BHC on Tuesday agreed to indirectly acquire DURECT Corp DRRX, including a novel therapeutic molecule, larsucosterol.
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic option for the treatment of patients with al...